The combined use of isoform-specific PKC inhibitors with antioxidants, MMPs inhibitors and cytokine antagonists may provide a multi-prong approach for treatment of Ca2+ antagonist-insensitive forms of HTN. This evidence concerns the gene PRRT2 and hypertensive disorder.